Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04533451
This trial studies the side effects of pembrolizumab with or without chemotherapy in treating
patients with stage IV non-small cell lung cancer that has come back (recurrent) and has
spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed
and carboplatin, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
pembrolizumab with or without chemotherapy may shrink the tumor in older patients with
non-small cell lung cancer.
Pembrolizumab, Pemetrexed, Carboplatin, Comprehensive Geriatric Assessment, Questionnaire Administration, Quality-of-Life Assessment
Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Aminah Jatoi, MD, John A. Ellerton, Jay W. Carlson, Bryan A. Faller, Daniel M. Anderson, Debra M. Prow, Brian C. Boulmay, Timothy R. Wassenaar, Adam M. Forman, Aqeel A. Gillani, Michael O. Ojelabi, Ben Yan, Rex B. Mowat, Kathleen J. Yost, Daniel Morgensztern, Timothy Dorius, Misbah U. Qadir, Bachir J. Sakr, William J. Irvin, Nicholas DiBella, Richard L. Deming, Priyank P. Patel, Theodore S. Thomas, John M. Schallenkamp, Alison K. Conlin, Erev E. Tubb, Carolyn J. Presley, James A. Wallace, Jeffrey J. Kirshner, Samer S. Kasbari, Mohammed Al-Jumayli, Mark A. Taylor, Lawrence E. Feldman, Howard M. Gross, William P. Fusselman, Kavitha Beedupalli, Rachit Kumar, Karen G. Zeman, Bret E. Friday, Jeffrey Crawford, Timothy D. Moore, Dan Sotirescu, Joyson Poulose, Mariam Alexander, Joshua Lukenbill, Albert S. DeNittis, Ki Y. Chung, Frank Weinberg, Nafisa D. Burhani, Roland T. Skeel, Ali Bukhari, Jonathan R. Thompson, Gregory A. Masters, Isoken Koko, Tareq Al Baghdadi, Douglas J. Weckstein, Ronald J. Scheff, Kenneth Angelino, Jennifer L. Heaberlin, Jonathan E. Dowell, Erin R. Alesi, Scott H. Okuno, Tyler Y. Kang, Shahzad Siddique, Qiwei W. Gai, Carole B. Miller, John C. McCann, Donald J. Jurgens, Bhavina B. Sharma, Susan E. Bates, Sarah W. Gordon, Jean G. Bustamante Alvarez, Patcharin Tanawattanacharoen

See list of participating sites